Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Heterogeneity in statin responses explained by variation in the human gut microbiome

View ORCID ProfileTomasz Wilmanski, View ORCID ProfileSergey A. Kornilov, View ORCID ProfileChristian Diener, View ORCID ProfileMathew Conomos, Jennifer C. Lovejoy, Paola Sebastiani, Eric S. Orwoll, View ORCID ProfileLeroy Hood, View ORCID ProfileNathan D. Price, View ORCID ProfileNoa Rappaport, View ORCID ProfileAndrew T. Magis, View ORCID ProfileSean M. Gibbons
doi: https://doi.org/10.1101/2021.12.02.21267193
Tomasz Wilmanski
1Institute for Systems Biology, Seattle, WA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Tomasz Wilmanski
Sergey A. Kornilov
1Institute for Systems Biology, Seattle, WA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Sergey A. Kornilov
Christian Diener
1Institute for Systems Biology, Seattle, WA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Christian Diener
Mathew Conomos
2University of Washington, Genetic Analysis Center, Seattle, WA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Mathew Conomos
Jennifer C. Lovejoy
1Institute for Systems Biology, Seattle, WA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paola Sebastiani
3Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eric S. Orwoll
4Oregon Health Sciences University, Portland, OR, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Leroy Hood
1Institute for Systems Biology, Seattle, WA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Leroy Hood
Nathan D. Price
5Onegevity (a division of Thorne HealthTech), New York, NY, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Nathan D. Price
Noa Rappaport
1Institute for Systems Biology, Seattle, WA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Noa Rappaport
  • For correspondence: noa.rappaport@isbscience.org amagis@isbscience.org sgibbons@isbscience.org
Andrew T. Magis
1Institute for Systems Biology, Seattle, WA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Andrew T. Magis
  • For correspondence: noa.rappaport@isbscience.org amagis@isbscience.org sgibbons@isbscience.org
Sean M. Gibbons
1Institute for Systems Biology, Seattle, WA, USA
6University of Washington, Department of Bioengineering, Seattle, WA, USA
7University of Washington, eScience Institute, Seattle, WA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Sean M. Gibbons
  • For correspondence: noa.rappaport@isbscience.org amagis@isbscience.org sgibbons@isbscience.org
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Statins remain one of the most prescribed medications worldwide. While effective in decreasing atherosclerotic cardiovascular disease risk, statin use is associated with several side effects for a subset of patients, including disrupted metabolic control and increased risk of type II diabetes. We investigated the potential role of the gut microbiome in modifying patient response to statin therapy. In a cohort of >1840 individuals, we find that the hydrolyzed substrate for 3-hydroxy-3-methylglutarate-CoA (HMG-CoA) reductase, HMG, may serve as a reliable marker for statin on-target effects. Through exploring gut microbiome associations between blood-derived measures of statin effectiveness and metabolic health parameters among statin users and non-users, we find that heterogeneity in statin response is associated with variation in the gut microbiome. A Bacteroides rich, α-diversity depleted, microbiome composition corresponds to the strongest statin on-target response, but also greatest disruption to glucose homeostasis, indicating lower treatment doses and/or complementary therapies may be beneficial in those individuals. Our findings suggest a potential path towards personalizing statin treatment through gut microbiome monitoring.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This work was supported by the M.J. Murdock Charitable Trust (to L.H. and N.D.P.), and Arivale. S.M.G., and C.D. were supported by a Washington Research Foundation Distinguished Investigator Award and by start-up funds from the Institute for Systems Biology. Further support came from the National Academy of Medicine Catalyst Award (to E.S.O, S.M.G., and L.H.) and a National Institutes of Health (NIH) grant (no. U19AG023122) awarded by the National Institute on Aging (NIA) (to P.S., E.S.O, and N.R.).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Procedures for the current study were run under the Western Institutional Review Board (WIRB) with Institutional Review Board (IRB) Study Number 20170658 at the Institute for Systems Biology and 1178906 at Arivale (both in Seattle, WA).

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • Introduction caption was added in the text to correct the abstract preview for the manuscript. Prior version included the abstract and the whole introduction in the preview.

Data Availability

Qualified researchers can access the full Arivale deidentified dataset supporting the findings in this study for research purposes through signing a Data Use Agreement (DUA). Inquiries to access the data can be made at data-access@isbscience.org and will be responded to within 7 business days.

https://github.com/gibbons-lab/mbtools

https://github.com/PriceLab/Statins_microbiome_project

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted December 10, 2021.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Heterogeneity in statin responses explained by variation in the human gut microbiome
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Heterogeneity in statin responses explained by variation in the human gut microbiome
Tomasz Wilmanski, Sergey A. Kornilov, Christian Diener, Mathew Conomos, Jennifer C. Lovejoy, Paola Sebastiani, Eric S. Orwoll, Leroy Hood, Nathan D. Price, Noa Rappaport, Andrew T. Magis, Sean M. Gibbons
medRxiv 2021.12.02.21267193; doi: https://doi.org/10.1101/2021.12.02.21267193
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Heterogeneity in statin responses explained by variation in the human gut microbiome
Tomasz Wilmanski, Sergey A. Kornilov, Christian Diener, Mathew Conomos, Jennifer C. Lovejoy, Paola Sebastiani, Eric S. Orwoll, Leroy Hood, Nathan D. Price, Noa Rappaport, Andrew T. Magis, Sean M. Gibbons
medRxiv 2021.12.02.21267193; doi: https://doi.org/10.1101/2021.12.02.21267193

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Public and Global Health
Subject Areas
All Articles
  • Addiction Medicine (216)
  • Allergy and Immunology (496)
  • Anesthesia (106)
  • Cardiovascular Medicine (1110)
  • Dentistry and Oral Medicine (196)
  • Dermatology (141)
  • Emergency Medicine (275)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (505)
  • Epidemiology (9796)
  • Forensic Medicine (5)
  • Gastroenterology (481)
  • Genetic and Genomic Medicine (2327)
  • Geriatric Medicine (223)
  • Health Economics (463)
  • Health Informatics (1567)
  • Health Policy (737)
  • Health Systems and Quality Improvement (608)
  • Hematology (238)
  • HIV/AIDS (508)
  • Infectious Diseases (except HIV/AIDS) (11669)
  • Intensive Care and Critical Care Medicine (617)
  • Medical Education (240)
  • Medical Ethics (67)
  • Nephrology (258)
  • Neurology (2154)
  • Nursing (134)
  • Nutrition (340)
  • Obstetrics and Gynecology (427)
  • Occupational and Environmental Health (519)
  • Oncology (1185)
  • Ophthalmology (366)
  • Orthopedics (129)
  • Otolaryngology (221)
  • Pain Medicine (148)
  • Palliative Medicine (50)
  • Pathology (314)
  • Pediatrics (699)
  • Pharmacology and Therapeutics (303)
  • Primary Care Research (268)
  • Psychiatry and Clinical Psychology (2195)
  • Public and Global Health (4685)
  • Radiology and Imaging (786)
  • Rehabilitation Medicine and Physical Therapy (458)
  • Respiratory Medicine (625)
  • Rheumatology (276)
  • Sexual and Reproductive Health (226)
  • Sports Medicine (212)
  • Surgery (252)
  • Toxicology (43)
  • Transplantation (120)
  • Urology (94)